The impact of neoadjuvant chemotherapy on patients with locally advanced breast cancer in a Nigerian semiurban teaching hospital: a single-center descriptive study.
BACKGROUND
There is a paucity of data on the response of breast cancer to neoadjuvant c in low-resources developing African countries such as Nigeria. We therefore decided to study the impact of neoadjuvant chemotherapy on breast cancer patients in Nigeria in the light of constrained resources.


METHODS
This was a single-center retrospective descriptive study. Sixty-two patients with locally advanced breast cancer treated with neoadjuvant chemotherapy in the last 24 years in Obafemi Awolowo University Teaching Hospital Complex (OAUTHC), Ile-Ife, Nigeria, constituted the study population. The outcome measures were clinical tumor response, disease-free survival, overall survival, and chemotherapy toxicity profile.


RESULTS
Patients ranged in age from 30 to 85 years (mean = 49.1 +/- SD 12.7 years) and included one male. After three cycles of chemotherapy, complete clinical response was observed in 4 patients (6.5%), partial clinical response in 28 patients (45.2%), no clinically measurable response in 24 patients (38.7%), and progressive disease in 6 patients (9.7%). Forty-one patients completed six cycles, of which 9 patients (22.0%) had complete clinical response and 12 patients (29.3%) had partial clinical response. Four of 30 patients (13.3%) with tumor size of 6-10 cm had complete clinical response, while no patient with a tumor bigger than 10 cm had complete clinical response. Of the 62 patients, 42 were followed up for more than 1 year. The 1-, 2-, and 5-year survival rates of this cohort were 66.7, 42.9, and 11.9%, respectively The median follow-up period was 9 months and the disease-free survival and overall survival rates at median follow-up period were 45 and 37%, respectively.


CONCLUSIONS
There was a poor overall clinical response rate to neoadjuvant chemotherapy in the Black population studied. Late presentation with large tumor mass may be accountable for this.
Arowolo
Olukayode Adeolu
OA
Department of Surgery, College of Health Sciences, Obafemi Awolowo University, Ile Ife, 220005, Osun State, Nigeria. arowolodoctor1@yahoo.com
Akinkuolie
Andrew Akinbolaji
AA
Lawal
Oladejo Olukayode
OO
Alatise
Olusegun Isaac
OI
Salako
Abdulkadir Ayo
AA
Adisa
Adewale Oluseye
AO
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018567:Breast Neoplasms, Male / Q000188:drug therapy; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006784:Hospitals, Teaching; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009549:Nigeria / Q000453:epidemiology; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil
Clin Oncol (R Coll Radiol). 1991 Mar;3(2):78-80
2031886
Clin Breast Cancer. 2005 Dec;6(5):391-401
16381622
Ann Oncol. 2001 May;12(5):685-91
11432629
Ann Oncol. 1998 Nov;9(11):1179-84
9862047
Surg Clin North Am. 2007 Apr;87(2):399-415, ix
17498534
J Clin Oncol. 1995 Mar;13(3):547-52
7884414
Rev Prat. 1998 Jan 1;48(1):21-7
9781206
J R Coll Surg Edinb. 1992 Jun;37(3):159-61
1404038
Breast J. 2006 Jan-Feb;12 Suppl 1:S3-15
16430397
Cancer Res. 1979 Oct;39(10):3861-5
476622
CA Cancer J Clin. 1996 Jan-Feb;46(1):5-27
8548526
Hong Kong Med J. 2000 Sep;6(3):265-8
11025844
Ann Surg Oncol. 2008 Jul;15(7):1983-8
18408976
Int J Radiat Oncol Biol Phys. 1992;23(5):949-60
1639655
Cancer. 1981 Jan 1;47(1):207-14
7459811
J Clin Oncol. 1997 Jul;15(7):2483-93
9215816
Cancer. 1994 Jul 1;74(1 Suppl):416-23
8004615
Ann Oncol. 1991 May;2(5):347-54
1954179
Ann Surg Oncol. 2003 Jul;10(6):635-44
12839848
Eur J Cancer. 1997 Jun;33(7):1075-107
9376190
Breast J. 2006 Jan-Feb;12 Suppl 1:S54-69
16430399
Asian J Surg. 2004 Apr;27(2):130-3
15140665
Eur J Cancer. 1994;30A(5):645-52
8080680
Oncol Rep. 2000 Mar-Apr;7(2):277-83
10671671
East Afr Med J. 2000 Oct;77(10):539-43
12862121
Afr J Reprod Health. 2001 Aug;5(2):56-62
12471913
Br J Surg. 1989 Feb;76(2):182-4
2702455
Breast J. 2006 Jan-Feb;12 Suppl 1:S38-53
16430398
West Afr J Med. 2005 Jul-Sep;24(3):209-13
16276696
Eur J Surg Oncol. 2009 Feb;35(2):113-22
18502088
J Clin Oncol. 2006 Apr 20;24(12):1940-9
16622270
Ann Oncol. 1994 Sep;5(7):591-5
7993833
Breast. 2006 Jun;15(3):399-409
16085418
Semin Oncol. 1996 Aug;23(4):464-74
8757273
Cancer. 2008 Oct 15;113(8 Suppl):2315-24
18837023
Oncologist. 2002;7(3):239-45
12065797
Eur J Cancer. 1991;27(12):1668-71
1782080
Eur J Cancer. 1995 Nov;31A(12):1969-75
8562150
Cancer Res. 1983 Apr;43(4):1488-92
6831397
Breast J. 2006 Jan-Feb;12 Suppl 1:S70-80
16430400
Ann Oncol. 1999 Jan;10(1):47-52
10076721
West Afr J Med. 2000 Apr-Jun;19(2):120-5
11070747
West Afr J Med. 2000 Jul-Sep;19(3):179-91
11126081
J Clin Oncol. 2002 Sep 1;20(17):3628-36
12202663
J Clin Oncol. 2002 Mar 1;20(5):1304-10
11870173